Cue Biopharma Inc【CUE】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cue Biopharma Announces Strategic Organizational Transition

Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO...

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival...

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Cue Biopharma Announces Proposed Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Hawkeye_tt 1月前

TY for that quick dip/Algo dump op. Took advantage big time.
GL all...

Hawk

👍️0

boston127 2月前

Momentum for CUE is waning,

as measured by a 14-period Slow Stochastic Oscillator. This means that investors are less aggressive in their recent purchases and may even be taking profits in positions bought at lower prices.

👍️0

boston127 2月前

The On Balance Volume indicator (OBV) is bullish.

The slope of the indicator is positive and suggests that buyers are presently more active than sellers.Today's volume was heavier than usual, trading 2,320,021 shares, versus an average of 389,835 shares per day during the last twelve months.

👍️0

boston127 2月前

Momentum for CUE is strongly bullish.

The 14-period Slow Stochastic oscillator is above 80, the level which many analysts call overbought. This means that investors have been actively purchasing shares and driving the price higher.

👍️0

boston127 2月前

I got in on Friday. Everything

about the company is good. Gotta love it. They did not give up much to get that $11M in financing. Will buy on dips. Bought a little more today.

Look at that Wkly candle ! Vol fantastic.
LT outlook back on !

Hawk

👍️0

Triple nickle 2月前

CUE ready to win 1.02

👍️0

Hawkeye_tt 2月前

Strong recovery on news....future looking good here. Buy, hold LT...
Hawk

CUE....this story grows quickly. Merck early investor.
Last few wks it has been breaking out.
$5 break next. More Partners want in, on top of Ono.

Hawk

👍️0

conix 3年前

CUE Insider Buy
Cue Biopharma Aaron G.L. Fletcher Director Buy 735,000 shares @ $4.76 $3,498,600.00 3/31/2022

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター